- World rank, 2022–2025
- #21,722 of 28,054 · #30,013 all time
- Rank in Switzerland
- #163 of 220
- Research works
- 166 ▲ 103% vs 2013–17
- Citations
- 2.5k 14.8 per fractional work
- Top-10% rate
- 21.2% record average 16.5%
- Open access
- 58% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 5.0×. Every wedge is a field page.
- Immunology and Microbiology 5.0×
- Economics, Econometrics and Finance 3.2×
- Medicine 3.0×
- Biochemistry, Genetics and Molecular Biology 2.3×
- Nursing 2.2×
- Veterinary 2.1×
- Mathematics 1.5×
- Health Professions 1.2×
- Chemical Engineering 0.8×
- Pharmacology, Toxicology and Pharmaceutics 0.7×
- Business, Management and Accounting 0.6×
- Agricultural and Biological Sciences 0.6×
- Neuroscience 0.5×
- Decision Sciences 0.4×
- Environmental Science 0.2×
- Computer Science 0.2×
- Chemistry 0.1×
- Engineering 0.1×
- Social Sciences 0.1×
- Psychology 0.1×
Which keywords describe research at Takeda (Switzerland)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Epidemiology, Pathogenesis, Vaccine Development, Vector Control, Vaccine, Arboviral Diseases, Zika Virus and Inflammatory Bowel Disease.
- Proton Pump Inhibitors
- Enzyme Replacement Therapy
- Clinical Outcomes
- Parkinson's Disease
- Targeted Therapy
- spike protein
- Thrombosis
- Mutation
- Immunity
- ACE2 Receptor
- Outbreak
- Coronavirus
- Inflammation
- Health Utility Measures
- Cost-effectiveness Analysis
- Genetics
- Quality of Life
- Arboviral Diseases
- Vector Control
- Pathogenesis
- Epidemiology
- Vaccine Development
- Vaccine
- Zika Virus
- Inflammatory Bowel Disease
- Immune Response
- Economic Evaluation
- Crohn's Disease
- Ulcerative Colitis
- SARS-CoV-2
- Transmission
- Ebola Virus
- Reservoirs
- Gene Therapy
- antibody
- Monoclonal Antibodies
- Genome Sequence
- Biopharmaceuticals
- Efficacy
- Lysosomal Storage Disorders
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Epidemiology16▲ 6.1×31 topics
- Pathogenesis7▲ 22×11 topics
- Vaccine Development7▲ 42×6 topics
- Vector Control6▲ 78×3 topics
- Vaccine6▲ 21×9 topics
- Arboviral Diseases5▲ 123×1 topic
- Zika Virus5▲ 123×1 topic
- Quality of Life5▲ 5.4×11 topics
- Inflammatory Bowel Disease5▲ 64×4 topics
- Genetics4▲ 9.6×6 topics
- Immune Response4▲ 10×11 topics
- Cost-effectiveness Analysis3▲ 61×1 topic
- Economic Evaluation3▲ 43×2 topics
- Health Utility Measures3▲ 61×1 topic
- Crohn's Disease3▲ 63×1 topic
- Inflammation3▲ 2.3×17 topics
- Ulcerative Colitis3▲ 109×1 topic
- Coronavirus2▲ 18×2 topics
- SARS-CoV-22▲ 12×3 topics
- Outbreak2▲ 92×2 topics
- Transmission2▲ 62×2 topics
- ACE2 Receptor2▲ 11×2 topics
- Ebola Virus2▲ 108×1 topic
- Immunity2▲ 7.0×3 topics
- Reservoirs2▲ 108×1 topic
- Mutation2▲ 14×2 topics
- Gene Therapy2▲ 13×2 topics
- Thrombosis2▲ 8.8×5 topics
- antibody2▲ 24×1 topic
- spike protein2▲ 24×1 topic
- Monoclonal Antibodies2▲ 26×3 topics
- Targeted Therapy2▲ 10×3 topics
- Genome Sequence1▲ 27×2 topics
- Parkinson's Disease1▲ 8.8×2 topics
- Biopharmaceuticals1▲ 41×3 topics
- Clinical Outcomes1▲ 9.7×3 topics
- Efficacy1▲ 28×2 topics
- Enzyme Replacement Therapy1▲ 115×1 topic
- Lysosomal Storage Disorders1▲ 140×1 topic
- Proton Pump Inhibitors1▲ 32×2 topics
Which research topics does Takeda (Switzerland) publish most on?
By volume in 2022–2025: Mosquito-borne diseases and control, Health Systems, Economic Evaluations, Quality of Life, Inflammatory Bowel Disease and Viral Infections and Outbreaks Research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Mosquito-borne diseases and control Public Health, Environmental and Occupational Health 5 works
- 2 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 3 works
- 3 Inflammatory Bowel Disease Genetics 3 works
- 4 Viral Infections and Outbreaks Research Infectious Diseases 2 works
- 5 SARS-CoV-2 and COVID-19 Research Infectious Diseases 2 works
- 6 Lysosomal Storage Disorders Research Physiology 1 works
- 7 Biosimilars and Bioanalytical Methods Immunology 1 works
- 8 Hemophilia Treatment and Research Hematology 1 works
- 9 Microscopic Colitis Epidemiology 1 works
- 10 Malaria Research and Control Public Health, Environmental and Occupational Health 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Takeda (Switzerland)'s research output changed?
Output in 2018–2022 was 103% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Zurich
- ETH Zurich
- University of Zurich
- University Hospital of Zurich
- Board of the Swiss Federal Institutes of Technology
- ABB (Switzerland)
- University Children's Hospital Zurich
- Zurich University of Applied Sciences in Business Administration
- Institute for Biomedical Engineering
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.